SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is gaining significant community traction as investors anticipate major exchange listings and positive momentum from Ethereum's evolving technical landscape. The community is actively discussing the platform's potential for cross-chain automation and is focused on holding through price volatility as they wait for increased market exposure.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant retail attention as community members rally behind its AI-powered infrastructure and ongoing development, with many investors actively accumulating the token on dips. The discussion is heavily centered on its potential for long-term utility within the Base ecosystem and high-conviction sentiment regarding its growth trajectory as an AI-native DeFi project.

Ventas, Inc. engages in the acquisition and ownership of seniors housing and healthcare properties. It operates through the following segments: Senior Housing Operating Portfolio (SHOP), Outpatient Medical and Research Portfolio (OM&R), and Triple-net Leased Properties (NNN). The SHOP segment is involved in owning and investing in senior housing communities throughout the United States and Canada. The OM&R segment refers to acquiring, owning, development, leasing and managing outpatient medical buildings and research centers throughout the United States. The NNN segment focuses on investing and owning senior housing communities, skilled nursing facilities, long-term acute care facilities, freestanding inpatient rehabilitation facilities, and other healthcare facilities throughout the United States and the United Kingdom. The company was founded in 1983 and is headquartered in Chicago, IL.

Ventas Inc

Ventas is drawing attention as investors highlight its resilient senior housing portfolio and demographic tailwinds, while the community actively debates its technical breakout potential toward higher price levels. Sentiment remains split between those focused on its defensive yield and long-term recovery story versus those concerned about macro headwinds and interest rate sensitivity.

Microchip Technology, Inc. engages in the provision of semiconductor products. It operates through the Semiconductor Products and Technology Licensing segments. The Semiconductor Products segment is involved in designing, developing, manufacturing, and marketing microcontrollers, development tools and analog, interface, mixed signal, connectivity devices, and timing products. The Technology Licensing segment offers license fees and royalties associated with technology licenses for the use of SuperFlash embedded flash and Smartbits one-time programmable technologies. The company was founded on February 14, 1989 and is headquartered in Chandler, AZ.

Microchip Technology, Inc.

Microchip Technology is trending as the community debates its recovery potential and valuation amid a challenging semiconductor cycle. Investors are closely monitoring its operational rebound following a recent cyberattack while weighing its long-term positioning in industrial, automotive, and data center markets.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors navigate aggressive swings driven by a mix of geopolitical tensions, central bank policy concerns, and sector-specific earnings. Community sentiment is deeply polarized, with active debates centered on whether the current semiconductor rally is a sustainable AI-driven shift or a speculative bubble vulnerable to a sharp correction.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors weigh the stock's recent volatility against its aggressive expansion into crypto trading and AI-integrated wealth management tools. The community remains divided, with many traders discussing the firm's system reliability and restrictions, while others view the pullback as a buying opportunity given the company's strong long-term client asset growth.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Community sentiment for XRP remains heavily influenced by the anticipated passage of the CLARITY Act, which investors believe will provide regulatory certainty and facilitate broader institutional integration for the token. Discussions are currently polarized between bulls who are actively accumulating on dips in expectation of a major price rally and skeptics who remain cautious due to historical price volatility and market structure concerns.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors digest its latest quarterly financial results and evaluate the company's long-term strategy for replacing revenue from Keytruda ahead of its patent expiration. The community is actively debating the stock's growth prospects, potential M&A activity within the oncology sector, and the competitive landscape of next-generation cancer therapies.

American Eagle Outfitters, Inc. is a multi-brand specialty retailer, which offers an assortment of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The firm operates stores in the United States, Canada, Mexico, Hong Kong, China and the United Kingdom. It also acquired two emerging brands to complement its existing brands, Tailgate, a vintage sports-inspired apparel brand, and Todd Snyder New York, a premium menswear brand. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters is experiencing heightened market activity driven by a potent mix of strong quarterly earnings, upbeat forward guidance, and highly effective celebrity-led marketing campaigns featuring Sydney Sweeney. While bullish investors are encouraged by the stock's momentum and significant short interest fueling squeeze potential, some community members express caution regarding its sustainability amidst broader retail sector pressures and recent rapid price appreciation.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is generating significant community buzz as a targeted vehicle for space infrastructure exposure, particularly due to its inclusion of private SpaceX shares. Traders are actively debating its potential as a momentum play, comparing it to other space-themed assets while monitoring its ability to capture upside from the broader aerospace sector and anticipated industry catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright &amp; Co. said the weaker revenue was likely due to seasonal factors rather than weakness in the company’s broader outlook.</li><li>The brokerage also cited higher-than-expected research and development expenses as a potential factor for the stock’s slump.</li><li>The firm’s target price of $10 represents a potential upside of over 730%.</li></ul>Shares of Invivyd, Inc (IVVD) plummeted more than 19% to their lowest level in over seven months after a disappointing first-quarter revenue miss rattled investor sentiment.&nbsp;Revenue for the first quarter (Q1) came in at $13.7 million, and though it represented a 22% growth from last year, it fell sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data. Invivyd reported a loss of $0.13 per share, compared to consensus estimates of a loss of $0.07 per share.Despite the subdued earnings report, one analyst views the steep selloff in the stock as “overdone.”<h2 class="st-heading-2">H.C. Wainwright Reiterates $10 Price Target For IVVD</h2>H.C. Wainwright &amp; Co. noted that the weaker revenue was likely due to seasonal factors and timing issues rather than weakness in the company’s broader outlook. The brokerage also cited higher-than-expected research and development expense of $30.7 million as a potential factor for the stock’s slump.The brokerage believes the higher expenses reflect “pivotal spend” ahead of the key VYD2311 readout expected in the third quarter. VYD2311 is Invivyd’s novel antibody being tested as a preventive and treatment option for COVID-19.The potential biologics license application (BLA) for VYD2311 is seen as the most important value driver of the stock, H.C. Wainwright added, while reiterating a ‘Buy’ rating and a $10 price target. This represents a potential upside of more than 730% from the stock’s current level.In December 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VYD2311. The designation is intended to accelerate the development and review of treatments for serious conditions and could shorten regulatory review and submission timelines.<h2 class="st-heading-2">Retail Fears IVVD Could Fall Below $1</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IVVD">IVVD</a> on Stocktwits remained in the ‘neutral’ territory, amid ‘high’ message volumes.One investor said they are hoping for a strong Phase 3 update, and noted that without positive trial results, Invivyd could become a sub-$1 stock.<stembedurl>https://stocktwits.com/gb2017384/message/653354127</stembedurl>The stock has shed more than 55% of its value so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/f-stock-rise-energy-storage-momentum-barclays-price-target/cZX1vw7ReST">F Stock Headed Toward Best Week In Nearly 6 Years On Energy Storage Momentum – Analyst Believes Execution And Scaling Remain Key</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%

Invivyd posted a first-quarter revenue of $13.7 million, sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data.

Equity

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -62.50% and -25.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are covering the company, MarketBeat reports. One equities...

Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063

Invivyd (NASDAQ:IVVD) provided updates on its REVOLUTION program for COVID-19 monoclonal antibody candidate VYD2311 and announced the discovery and early development work for a measles monoclonal antibody candidate, VMS-063, during a conference call led by board chairman Marc Elia alongside Chief Sc...

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS063 toward clinical development.read more...

Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and t...

FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - HC Wainwright reduced their FY2027 EPS estimates for shares of Invivyd in a research report issued to clients and investors on Tuesday, March 10th. HC...

$IVVD Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.13 up 7.14% YoY
• Reported revenue of $13.74M up 21.59% YoY

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.13 up 7.14% YoY
• Reported revenue of $13.74M up 21.59% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

IVVD
Invivyd Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Earnings Recap

Latest IVVD News

IVVDInvivyd Inc